## Does the World Now Have 306 Active Gene-Editing Clinical Trials?

**306 publicly disclosed gene-editing clinical trials** are now tracked in the CRISPR Medicine News Global Clinical Trials Database 2.0, according to CMN Intelligence's Q2 2026 report published today. The database is manually curated by the CMN Intelligence team and represents, by the organization's own description, the only manually curated global database of its kind. The snapshot reflects trials as of 31 July 2026. The United States and China lead all countries by trial count, followed by the United Kingdom, Australia, Canada, and several European nations. The report also examines editing approach, cell source, and delivery technologies across the full trial landscape — though those detailed breakdowns sit behind CMN Intelligence's paid access tier.

For the gene-editing field, 306 trials is a consequential number. [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) moved from Nobel Prize to its first approved therapy (Casgevy, sickle cell disease) in roughly a decade. The density of trials now in the clinic suggests the field is past proof-of-concept and into a broader competitive phase across disease areas, geographies, and editing modalities.

---

## What the 306-Trial Count Actually Means

The headline figure requires some interpretation before drawing conclusions about industry momentum.

**Manual curation matters — and limits.** CMN Intelligence explicitly distinguishes its database as manually curated, not algorithmically scraped from ClinicalTrials.gov or equivalent registries. That methodology catches trials that may not appear in standard registry searches and filters out duplicates or withdrawn trials that inflate automated counts. The trade-off is that manual curation is resource-intensive and introduces a lag; this edition reflects a 31 July 2026 cut-off, meaning trials initiated in August or September 2026 are not captured.

**"Publicly disclosed" is a qualifier, not a technicality.** A meaningful share of gene-editing clinical activity — particularly in China — has historically operated below the disclosure threshold that Western registries require. The 306 figure represents what CMN Intelligence could verify from public sources. Actual global trial volume is likely higher.

**Geographic concentration signals regulatory maturity differentials.** The US–China dominance of trial counts is expected given their respective IND/IND-equivalent approval throughput and available patient populations. The appearance of Australia and Canada alongside multiple European nations suggests the regulatory infrastructure for gene-editing trials is maturing beyond the two dominant markets — an important signal for companies evaluating trial geography strategy.

---

## Adjacent Signals Worth Watching

The CMN Q2 2026 report drops alongside several concrete clinical data points that provide qualitative texture to the 306-trial count:

- **Xenotransplantation durability:** The source references a gene-edited pig kidney that kept a patient with end-stage kidney disease dialysis-free for 271 days before failing and being surgically removed. That duration represents a meaningful data point for the xenotransplantation field, even in the context of ultimate graft failure.

- **Intellia's regulatory milestone:** The US FDA accepted Intellia Therapeutics' application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002), an in vivo CRISPR-Cas9 program. FDA acceptance of the filing is a procedural milestone, not an approval — but it confirms the agency is processing in vivo [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) applications at the BLA/NDA stage.

- **CTX310 lipid data:** A single intravenous dose of CRISPR Therapeutics' CTX310 — targeting ANGPTL3 — reduced circulating triglycerides and LDL in a reported cohort. Single-dose durability data for an in vivo lipid-lowering program is directly relevant to competitive positioning against approved small-molecule and antibody-based lipid therapies.

- **mRNA delivery for HSC editing:** Delivering [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9) as mRNA in lipid nanoparticles preserved fitness and erythroid potential in edited human haematopoietic stem and progenitor cells (HSPCs). For [cell therapy](https://synbiointel.com/glossary/cell-therapy) developers, HSPC fitness post-editing is a persistent manufacturing bottleneck; mRNA-based delivery that maintains engraftment potential is a credible path around viral vector-associated genotoxicity concerns.

---

## Skeptical Read: What the Report Does Not Tell Us

The CMN Q2 2026 report is a curated count, not an outcomes database. Trial registration does not equal clinical activity — some registered trials are on clinical hold, enrolling slowly, or paused for safety reviews. The report's full breakdown of editing approach (presumably [base editing](https://synbiointel.com/glossary/base-editing), prime editing, nuclease-based CRISPR, and potentially TALENs/zinc fingers for older programs), cell source (autologous vs. allogeneic, ex vivo vs. in vivo), and delivery technology is paywalled, which limits independent verification of the distribution.

The 306 count also conflates Phase I safety studies — most of which will not advance — with later-stage efficacy trials. A count weighted by phase would give a clearer picture of near-term commercial potential.

That said, a manually curated 306-trial database from a dedicated editorial team remains more reliable as a benchmark than automated registry aggregations, which routinely double-count or include terminated studies.

---

## Industry Trajectory

The trial count trajectory reinforces a view that gene-editing clinical development has entered an industrialization phase. The science is no longer the rate-limiting step for most established modalities. Bottlenecks are now manufacturing scale (particularly GMP-grade viral and non-viral delivery), regulatory pathway clarity for in vivo editors, and long-term safety surveillance infrastructure for approved products.

For investors, the geographic breakdown — US, China, UK, Australia, Canada, Europe — signals that gene-editing therapeutics are developing a global clinical infrastructure that will eventually support global commercial launches, not just US-first strategies. Companies building manufacturing and regulatory capabilities in multiple jurisdictions now have a structural advantage.

---

## Key Takeaways

- CMN Intelligence's manually curated Global Clinical Trials Database 2.0 counts **306 publicly disclosed gene-editing trials** as of 31 July 2026.
- The **United States and China lead** by trial count; the UK, Australia, Canada, and several European countries follow.
- The database is the only manually curated global registry of its kind — methodology matters for count reliability relative to automated scrapes.
- Adjacent clinical signals include a gene-edited pig kidney sustaining 271 dialysis-free days, FDA acceptance of Intellia's lonvo-z application, and single-dose ANGPTL3 suppression data from CRISPR Therapeutics' CTX310.
- The 306-trial headline figure masks phase distribution, trial status, and geographic concentration details available only in the full paid report.
- Gene-editing clinical development is in an industrialization phase; manufacturing scale and regulatory infrastructure are now the primary rate-limiters, not molecular biology.

---

## Frequently Asked Questions

**How many gene-editing clinical trials are currently active globally?**
CMN Intelligence's manually curated database counts 306 publicly disclosed gene-editing clinical trials as of 31 July 2026. This figure covers trials that had reached public disclosure by that date; actual global volume, particularly from less-disclosed jurisdictions, may be higher.

**Which countries are leading in CRISPR and gene-editing clinical trials?**
According to the CMN Q2 2026 report, the United States and China lead by trial count, followed by the United Kingdom, Australia, Canada, and several European countries.

**What is the CMN Intelligence Global Clinical Trials Database 2.0?**
It is a manually curated database maintained by CRISPR Medicine News' intelligence team, tracking publicly disclosed gene-editing clinical trials worldwide. CMN describes it as the only manually curated database of its kind, distinguishing it from algorithmically aggregated registry data.

**What editing technologies are covered in the CMN database?**
The Q2 2026 report examines editing approach, cell source, and delivery technologies across the global landscape, though the full breakdown by modality is available only in the paid report. Publicly, the database covers the broader gene-editing field, which includes CRISPR-based systems and other programmable nucleases.

**What does the 306-trial count mean for investors in gene-editing companies?**
It signals that clinical gene-editing has moved past early proof-of-concept into a broad competitive phase. The near-term investment signal lies in the phase distribution (not disclosed publicly), delivery technology trends, and which geographic markets are driving enrollment — factors that distinguish programs likely to generate pivotal data in the next two to three years from early safety studies with long runways ahead.